Updates are available Correction dated 2026-02-18
Click to view Correction: https://doi.org/10.1038/s41589-026-02174-5
-
Authors
Zhou, Jia-Xin
Shao, Zhen-Yu https://orcid.org/0000-0003-0355-4191
Zhang, Lin https://orcid.org/0000-0002-3076-6993
Guo, Jian-Nan
Wang, Meng
Xu, Qin https://orcid.org/0000-0002-5860-8225
Wang, Yi-Qin
Xu, Qing
Zhou, Dan
Ren, Sheng-Xiang
Yu, Yan-Hao
Lu, Zhi-Hao
Pang, Guo-Zheng
Cao, Yao
Liu, Yi-Lin
Zhou, Bin
Ji, Hong-Bin
Chen, Yi-Han https://orcid.org/0000-0003-1000-1835
Wu, Hai-Ping https://orcid.org/0009-0009-8918-6043
Xu, Guo-Liang
Zhang, Liang https://orcid.org/0000-0002-7672-1168
Du, Ya-Rui https://orcid.org/0009-0004-2094-9325
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (31991163)
National Natural Science Foundation of China (32370632)
National Natural Science Foundation of China (21572133)
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 11 November 2025
First Online: 22 January 2026
Change Date: 18 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-026-02174-5
Competing interests
: G.-L.X. and H.-P.W. are cofounders of Cytosinlab Therapeutics. J.-N.G., M.W., Y.C. and Y.-L.L. are employees of Cytosinlab Therapeutics. Cytosinlab Therapeutics is the owner of a patent application (application number 2023118384448) covering the development of TDG inhibitor C-271 (internal code CTS2711 at Cytosinlab Therapeutics). The other authors declare no competing interests.
